Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 157-160 , February 2010

Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage

Received 22 June 2009 ,Revised 27 October 2009 ,Accepted 2 November 2009.

References 

  1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–176
  2. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988;318:1315–1321
  3. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr. Pharm. Des. 2008;14:953–961
  4. Yamamoto H, Watanabe T, Yamamoto Y, Yonekura H, Munesue S, Harashima A, et al. RAGE in diabetic nephropathy. Curr. Mol. Med. 2007;7:752–757
  5. Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy—are these receptors valid therapeutic targets. Curr. Drug Targets. 2009;10:42–50
  6. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 2004;279:50019–50024
  7. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 2003;370:1097–1109
  8. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care. 2005;28:2716–2721
  9. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia. 2009;52:705–714
  10. Humpert PM, Kopf S, Djuric Z, Wendt T, Morcos M, Nawroth PP, et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care. 2006;29:1111–1113
  11. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 2007;6:9
  12. Sampson MJ, Drury PL. Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight, and serum creatinine. Diabetes Care. 1992;15:609–612
  13. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 2006;13:1971–1978
  14. dash;S American Diabetes Association . Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl. 1):S13–S61
  15. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 2005;16:2363–2372
  16. Kanková K, Kalousová M, Hertlová M, Krusová D, Olsovský J, Zima T. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch. Physiol. Biochem. 2008;114:111–119
  17. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin. Exp. Med. 2007;7:188–190
  18. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 2008;76:52–56
  19. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia. 2006;49:2756–2762
  20. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000;11:1656–1666
  21. Yamagishi S, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler. Thromb. Vasc. Biol. 2007;27:e33–34
  22. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008;34:392–395

PII: S0168-8227(09)00473-2

doi: 10.1016/j.diabres.2009.11.002

Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 157-160 , February 2010

Article Tools